Nkarta (NKTX) Total Non-Current Liabilities (2019 - 2026)
Nkarta (NKTX) posted quarterly Total Non-Current Liabilities of $86.1 million for Q1 2026, down 6.1% year-over-year from $91.7 million in Q1 2025, and down 6.18% quarter-over-quarter from $91.8 million in Q4 2025.
Nkarta (NKTX) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Nkarta's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $86.1 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 6.1% year-over-year to $86.1 million; the TTM figure through Mar 2026 stood at $86.1 million (down 6.1% YoY), while the FY2025 annual figure was $91.8 million, down 1.44% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $86.1 million, down from $91.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $104.5 million in Q3 2022, with the low at $77.6 million in Q1 2022.
- The 4-year median for Total Non-Current Liabilities is $90.6 million (2025), against an average of $89.7 million.
- The sharpest annual moves came in 2022 and 2026: Total Non-Current Liabilities surged 366.69% in 2022, then dropped 6.1% in 2026.
- Nkarta's Total Non-Current Liabilities stood at $104.5 million in 2022, then slipped by 10.9% to $93.1 million in 2024, then fell by 1.44% to $91.8 million in 2025, then dropped by 6.18% to $86.1 million in 2026.
- Business Quant data shows NKTX's Total Non-Current Liabilities at $86.1 million in Q1 2026, $91.8 million in Q4 2025, and $89.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 89.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.82 Mn |
| Mar 31, 2026 | 86.13 Mn |
| Dec 31, 2025 | 91.80 Mn |
| Sep 30, 2025 | 89.25 Mn |
| Jun 30, 2025 | 90.56 Mn |
| Mar 31, 2025 | 91.72 Mn |
| Dec 31, 2024 | 93.14 Mn |
| Sep 30, 2022 | 104.53 Mn |
| Jun 30, 2022 | 82.59 Mn |
| Mar 31, 2022 | 77.58 Mn |
| Dec 31, 2021 | 22.92 Mn |
| Sep 30, 2021 | 22.40 Mn |
| Jun 30, 2021 | 20.66 Mn |
| Mar 31, 2021 | 19.63 Mn |
| Dec 31, 2020 | 16.35 Mn |
| Sep 30, 2020 | 17.22 Mn |
| Jun 30, 2020 | 67.57 Mn |
| Dec 31, 2019 | 13.95 Mn |